- Home
- AVD vs FLNA Comparison
AVD vs FLNA Comparison
Compare AVD & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVD | FLNA |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 61.8M |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | AVD | FLNA |
|---|---|---|
| Price | $2.20 | $0.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 295.1K | 272.8K |
| Earning Date | 03-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $515,114,000.00 | $41,119,000.00 |
| Revenue This Year | $8.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.03 | $0.85 |
| 52 Week High | $5.92 | $2.03 |
Technical Indicators
Market Signals| Indicator | AVD | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 42.83 |
| Support Level | $2.03 | $0.85 |
| Resistance Level | $2.67 | $0.99 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 47.06 | 38.49 |
Price Performance
Historical ComparisonAbout AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. The company is a manufacturer of specialty solutions that develops and markets safe synthetic, biological, and biorational products for agricultural, commercial, and consumer uses. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.